@entity19006 reduces @entity11648 in XXXX Stage 3 @entity1 .

@entity1 @entity14104 @entity19006 @entity11648 @entity740 @entity1391 @entity3151 @entity461
BACKGROUND: In @entity740 ( @entity740 ) @entity1 , the ability to excrete a @entity1391 load is impaired. Compensatory increase in @entity461 ( @entity461 ) and @entity11648 ( @entity11648 ) promote @entity14104 . Serum @entity11648 concentration is considered an early biomarker of excess @entity1391 load and high levels of @entity11648 have been associated with increased mortality. In the present study, we have evaluated the changes in plasma @entity11648 after treatment with the @entity1391 binder @entity19006 in @entity1 with @entity740 -3 and a normal serum @entity1391 concentration. METHODS: Eighteen Caucasian @entity740 Stage 3a/3b patients with serum @entity1391 <4.5 mg/dL were recruited in a prospective longitudinal open-label study. @entity1 received a 4-week period of standardized @entity3151 -restricted diet containing 0.8 g/Kg/day protein. Thereafter, the same diet was maintained and @entity1 received @entity19006 (750 mg with the three main meals) for 4 weeks. RESULTS: No significant changes were observed in serum @entity1391 , however, @entity19006 significantly decreased urinary excretion of @entity1391 and fractional excretion of @entity1391 (P < 0.004). This was accompanied by a significant decrease in carboxyterminal @entity11648 (median percent change from baseline -21.8% (interquartile range -4.5, -30%), P = 0.025). No changes were observed in @entity461 . CONCLUSIONS: In conclusion, @entity19006 reduced @entity1391 load, as assessed by urinary @entity1391 excretion, and also reduced plasma @entity11648 in @entity740 -3 @entity1 . This occurs in the presence of unchanged normal serum @entity1391 levels.
